CareDx (NASDAQ:CDNA) Given New $21.00 Price Target at Wells Fargo & Company

CareDx (NASDAQ:CDNA) had its target price boosted by investment analysts at Wells Fargo & Company from $18.00 to $21.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 14.42% from the stock’s current price.

Several other brokerages have also recently issued reports on CDNA. Zacks Research raised shares of CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Weiss Ratings restated a “hold (c-)” rating on shares of CareDx in a research report on Monday, December 29th. Craig Hallum downgraded CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective on the stock. in a research report on Tuesday, January 6th. BTIG Research upped their target price on CareDx from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Wall Street Zen lowered CareDx from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, CareDx has an average rating of “Hold” and an average target price of $27.17.

CareDx Stock Performance

Shares of CDNA traded down $0.90 during trading hours on Wednesday, hitting $18.35. 448,972 shares of the stock were exchanged, compared to its average volume of 704,670. The stock’s 50-day moving average price is $19.68 and its two-hundred day moving average price is $16.74. CareDx has a 12-month low of $10.96 and a 12-month high of $22.95. The company has a market cap of $943.95 million, a price-to-earnings ratio of 15.05 and a beta of 2.51.

CareDx (NASDAQ:CDNA) last announced its earnings results on Tuesday, February 24th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.12). The business had revenue of $108.39 million for the quarter, compared to analyst estimates of $102.76 million. CareDx had a return on equity of 20.15% and a net margin of 19.65%.The company’s revenue for the quarter was up 25.2% compared to the same quarter last year. During the same period last year, the firm earned $0.18 EPS. On average, research analysts expect that CareDx will post -0.9 earnings per share for the current year.

Insider Buying and Selling at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total value of $407,964.80. Following the sale, the chief executive officer directly owned 597,405 shares of the company’s stock, valued at approximately $12,641,089.80. The trade was a 3.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 29,636 shares of company stock worth $625,949 in the last ninety days. 4.40% of the stock is owned by company insiders.

Institutional Trading of CareDx

Several institutional investors have recently added to or reduced their stakes in CDNA. Price T Rowe Associates Inc. MD lifted its stake in CareDx by 1.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock worth $739,000 after purchasing an additional 711 shares in the last quarter. Cetera Trust Company N.A lifted its stake in CareDx by 11.2% during the 2nd quarter. Cetera Trust Company N.A now owns 12,195 shares of the company’s stock worth $238,000 after acquiring an additional 1,225 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in CareDx by 5.9% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 22,509 shares of the company’s stock valued at $440,000 after acquiring an additional 1,264 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in CareDx by 4.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after acquiring an additional 1,280 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey grew its position in CareDx by 12.2% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 11,885 shares of the company’s stock valued at $232,000 after acquiring an additional 1,293 shares in the last quarter.

More CareDx News

Here are the key news stories impacting CareDx this week:

• Positive Sentiment: Q4 revenue topped Street estimates and showed robust year‑over‑year growth (quarterly revenue ~$108.4M, ~25% YoY), supporting the company’s top‑line momentum. CareDx Q4 2025 Highlights
• Positive Sentiment: Management updated FY‑2026 revenue guidance to a range (~$420M–$444M) that sits above consensus (~$417.5M), which likely helped sentiment despite the EPS miss.
• Positive Sentiment: Leadership move: COO Keith Kennedy will also assume CFO responsibilities, giving investors clarity on finance leadership during the transition. BusinessWire: CFO Appointment
• Neutral Sentiment: Company released the full earnings presentation and call transcript/slides — useful for modeling but not market-moving by itself. Earnings Presentation
• Negative Sentiment: Q4 EPS missed consensus: reported $0.12 vs. consensus ~$0.24, which disappointed earnings-focused investors and pressured margins/earnings durability questions. Zacks: Q4 Earnings Miss
• Negative Sentiment: Some transcripts/reporting show conflicting EPS figures (one transcript cites an adjusted/GAAP discrepancy with a negative EPS figure), adding short‑term uncertainty around reported metrics and adjustments. Earnings Call Transcript

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.